Holen Sie sich die Stockscreener-App
25.05
0.22%
-15.91
Handel nachbörslich:
25.05
-0.000100
-0.00%
Schlusskurs vom Vortag:
$9.14
Offen:
$25.07
24-Stunden-Volumen:
4,261
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-13.32
EPS:
-1.88
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
-2.04%
6M Leistung:
+10.95%
1J Leistung:
-15.87%
1-Tages-Spanne:
$25.03
$25.07
1-Wochen-Bereich:
$25.03
$25.07
52-Wochen-Spanne:
$25.03
$25.07
Flexion Therapeutics, Inc. Stock (FLXN) Company Profile
Firmenname
Flexion Therapeutics, Inc.
Sektor
Telefon
781-305-7777
Adresse
10 Mall Road, Suite 301, Burlington
Compare FLXN vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FLXN
Flexion Therapeutics, Inc.
|
25.05 | 0 | 0 | 0 | 0 | 0.00 |
TAK
Takeda Pharmaceutical Co Adr
|
15.84 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.95 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.84 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
544.33 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-08-20 | Eingeleitet | Goldman | Neutral |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-29 | Eingeleitet | Credit Suisse | Outperform |
| 2020-06-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2019-12-27 | Bestätigt | The Benchmark Company | Buy |
| 2019-12-05 | Eingeleitet | Craig Hallum | Buy |
| 2019-11-25 | Eingeleitet | BTIG Research | Buy |
| 2019-05-09 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2019-01-04 | Bestätigt | Needham | Buy |
| 2019-01-04 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2018-06-28 | Eingeleitet | The Benchmark Company | Buy |
| 2017-10-09 | Bestätigt | Needham | Buy |
| 2017-08-24 | Eingeleitet | Northland Capital | Outperform |
| 2016-12-22 | Eingeleitet | Raymond James | Strong Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-07-21 | Eingeleitet | Lake Street | Buy |
| 2016-05-03 | Fortgesetzt | Wells Fargo | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-09-09 | Bestätigt | Needham | Buy |
Alle ansehen
Flexion Therapeutics, Inc. Aktie (FLXN) Neueste Nachrichten
Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com
FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill
Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com
Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com
Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal
Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - Akin
Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Intra-Articular Injections Market Size to Hit USD 13.65 Billion by 2035 - Precedence Research
Joint Pain Injections Market Overview and Leading Players: - openPR.com
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz
Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in
Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN
Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN
Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN
Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research
Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research
Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - BioSpace
Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail
Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma
Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us
Knee Osteoarthritis Treatment Market Size, Share | CAGR Of 7.7% - Market.us
Knee Osteoarthritis Injectable Treatments Market Size to Hit USD 6.78 Billion by 2035 - Precedence Research
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Catalyst Pharmaceuticals Appoints Dr. William T. Andrews as Chief Medical Officer | CPRX Stock News - Quiver Quantitative
Anti-Inflammatory Therapeutics Market Size, Value & Trends | By 2033 - Straits Research
Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest Technology
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer - GlobeNewswire
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Osteoarthritis Treatment Market 2032: FDA Approvals, Clinical - openPR.com
Pacira BioSciences Reports Second Quarter 2024 Financial Results - GlobeNewswire
Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as Chief Medical Officer - citybiz
Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire
Ocular Therapeutix Appoints Steve Meyers as Chief Commercial Officer - citybiz
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire
Finanzdaten der Flexion Therapeutics, Inc.-Aktie (FLXN)
Es liegen keine Finanzdaten für Flexion Therapeutics, Inc. (FLXN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.45%
3.01%
Kapitalisierung:
|
Volumen (24h):